BERNARDSVILLE, N.J., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Anima Biotech, the leader in the discovery of drugs that specifically control mRNA translation, today announced the company will present at the 17^th Annual Discovery on Target conference in its inaugural RNA as a Drug Target program taking place in Boston, MA, September 16-19, 2019.

Kevin Pong, Ph.D., Vice President of Business Development of Anima Biotech, will present an overview of the company’s Translation Control Therapeutics technology for the discovery of small molecule drugs that specifically control mRNA translation. He will give insight into Anima Biotech’s business endeavors, partnering activities, and new approach targeting proteins that regulate translation opening an entirely novel drug target space.

Details regarding the company’s presentation are as follows:

Event: 2019 Inaugural RNA as a Drug Target Program at the 17^th Annual Discovery on Target Conference
Date: Thursday, September 19, 2019
Time: 8:45 a.m. EDT
Room: Essex North
Venue: Westin Copley Place, Boston, MA

About Anima Biotech

Anima Biotech is advancing Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against many diseases. With novel biology that monitors the translation of proteins and proprietary cloud-based analysis software, we identify drug candidates that modulate a target protein’s production. We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Our approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations. To learn more about us, visit https://www.animabiotech.com

Media Contact:
Andrew Mielach
LifeSci Public Relations
+1.646.876.5868
amielach@lifescipublicrelations.com